Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (November 2016)
23 slides from Clearpoint Neuro's investor presentation, Nov 4, 2016
Slide 1: Investor Presentation November 2016
Ticker: MRIC Investor Presentation November, 2016 Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as “an
Slide 3: MRI Interventions Investment Opportunity
MRI Interventions Investment Opportunity Focused commercial effort in neurosurgery; FDA/CE cleared Commercial products Business ClearPoint ® System enables real-time MRI guidance for multiple procedures in neurosurgery Products are FDA-cleared, CE-marked; 45+ hospitals Capital equipment sale leads t
Slide 4: Key Procedures for Our Technology and the challenges we address
Key Procedures for Our Technology …and the challenges we address Therapies Patient Populations Key Challenges We Address Deep Brain Stimulation 65% plus opt-out rate for DBS due Parkinson’s to fear of surgery itself Medtronic Disease; Elimination of stereotactic St. Jude* Dystonia headframe; patient
Slide 5: ClearPoint Neuro Navigation System
ClearPoint ® Neuro Navigation System Utilizes an existing diagnostic or intraoperative MRI to enable real time, intra-operative MRI Imaging during Neurosurgery ClearPoint Software Proprietary software for targeting and trajectory calculation / determination Dicom image based MRI Safe Hardware MRI sa
Slide 6: Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed Blind
Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed “Blind” Conventional Stereotactic Procedure ClearPoint Neuro Procedure No real time images – images from earlier in the day or week 80% of interviewed neurosurgeons/neurologists believe real time MRI-guidance will or can become th
Slide 7: ClearPoint Procedure Overview: Target Selection & Entry Planning
ClearPoint Procedure Overview Target Selection & Entry Planning © 2016 MRI INTERVENTIONS, INC. | 7
Slide 8: ClearPoint Procedure Overview: Trajectory Alignment & Device Insertion
ClearPoint Procedure Overview SmartFrame ® Trajectory Guide Trajectory Alignment & Device Insertion SmartFrame ® Hand Controller © 2016 MRI INTERVENTIONS, INC. | 8
Slide 9: Clinical Support, Validation
Clinical Support, Validation Notable Neurosurgeon Supporters Dr. Philip Starr ASSFN Past President Dr. Paul Larson UCSF & VA Dr. Robert Gross Emory University Dr. Robert Wharen, Jr. Mayo Clinic -Jacksonville Dr. Krys Bankiewicz Bankiewicz Lab, UCSF Dr. Russ Lonser OSU - NUH Published Peer-Reviewed J
Slide 10: Patented Intellectual Property
Patented Intellectual Property Over 100 issued patents around the world 20+ U.S. 30+ OUS 70+ U.S. Patents 45+ OUS Patents Patent Applications Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrame ® trajectory guide; othe
Slide 11: MRIC's Unique Opportunity in Drug Delivery
MRIC’s Unique Opportunity in Drug Delivery Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery (pills, shots, IV) of almost all drugs 98% of small molecules - Direct injection without ClearPoint is blind, so target is frequently missed - Neopharm Trial -
Slide 12: ClearPoint Drug Delivery w/ SmartFlow Cannula
ClearPoint Drug Delivery w/ SmartFlow ® Cannula SmartFrame targeting cannula, visible under MRI SmartFlow Cannula Inserted to target in the brain Drug infusion is visible under real-time MRI Highly precise delivery is evident in the putamen Example of MR-guided infusion of AAV2-AADC in a patient fro
Slide 13: ClearPoint Drug Delivery w/ SmartFlow Cannula
ClearPoint Drug Delivery w/ SmartFlow Cannula MR visualization of neuro target MR-guided placement of catheter Therapeutic agent delivered under MR-guidance* Specialized, FDA-cleared drug delivery cannula’s / catheters Conclusion: The ClearPoint system allows Real-time Convection-enhanced Delivery t
Slide 14: ClearPoint's Use in Drug Delivery: Seven Programs Underway
ClearPoint’s Use in Drug Delivery Seven Programs Underway Now... Current Drug Delivery Trials Utilizing the ClearPoint System: AAV2-hAADC for Parkinson’s disease Phase 1 Study at UCSF Initial sponsorship by Michael J. Fox Foundation AAV2-GDNF for Parkinson’s disease Phase 1 Study at the NIH MDNA55fo
Slide 15: ClearPoint Revenue Model
ClearPoint Revenue Model BUSINESS MODEL - RAZOR / RAZORBLADE ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint Disposables: $7,500 (average) ASP per procedure with potentially strong margins Recurring revenue from the sale of disposables Procedures covered by existing inpatient DRG re
Slide 16: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint Installed Base of 45 sites in the US Europe: Warsaw, Poland © 2016 MRI INTERVENTIONS, INC. | 16
Slide 17: ClearPoint US Market Opportunity
ClearPoint US Market Opportunity Parkinson’s Epilepsy Brain Tumors Total Prevalence (US) 1,500,000 2,200,000 80,000 (annual diagnosis) Prevalence Drug Treatment 125,000 264,000 Resistant (DTR) 7,500 18,000 Resections: 80,000 Incidence DTR Stereotactic Biopsy: 10,000 Electrode Laser Ablation Biopsy /
Slide 18: ClearPoint Consumable Revenues
ClearPoint Consumable Revenues © 2016 MRI INTERVENTIONS, INC. | 18
Slide 19: Total Revenue, 2014 - 2016
Total Revenue, 2014 - 2016 © 2016 MRI INTERVENTIONS, INC. | 19
Slide 20: Cash Flow From Operations
Cash Flow From Operations © 2016 MRI INTERVENTIONS, INC. | 20
Slide 21: Experienced, Medical Device Leadership Team
Experienced, Medical Device Leadership Team Key Management Executive Title Prior Experience Frank Grillo President, CEO Peter Piferi COO Wendelin Maners VP Marketing Robert Korn VP Sales Hal Hurwitz CFO Board of Directors Kimble Jenkins, Maria Sainz Dr. Phillip Pizzo Pascal Girin Timothy Frank Grill
Slide 22: Leading a New, Emerging Industry Trend
Leading a New, Emerging Industry Trend © 2016 MRI INTERVENTIONS, INC. | 22
Slide 23: MRI Interventions, Inc. Contact
Ticker: MRIC MRI Interventions, Inc. Irvine, CA 949.900.6833 www.mriinterventions.com Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 23
MRI Interventions — Investor Presentation (November 2016) on 6ix